Innate Pharma S.A.
IPHA
$2.03
$0.02051.02%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 948.20K | 879.20K | 2.31M | 2.38M | 4.46M |
| Total Other Revenue | 1.81M | 1.68M | 1.84M | 1.89M | 2.18M |
| Total Revenue | 2.76M | 2.56M | 4.14M | 4.27M | 6.64M |
| Cost of Revenue | 11.64M | 10.80M | 12.21M | 12.59M | 15.65M |
| Gross Profit | -8.89M | -8.24M | -8.06M | -8.32M | -9.00M |
| SG&A Expenses | 5.54M | 5.14M | 5.40M | 5.57M | 5.16M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 17.19M | 15.94M | 17.61M | 18.16M | 20.80M |
| Operating Income | -14.43M | -13.38M | -13.46M | -13.89M | -14.16M |
| Income Before Tax | -12.11M | -11.23M | -13.17M | -13.58M | -13.33M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -12.11M | -11.23M | -13.17M | -13.58M | -13.33M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -12.11M | -11.23M | -13.17M | -13.58M | -13.33M |
| EBIT | -14.43M | -13.38M | -13.46M | -13.89M | -14.16M |
| EBITDA | -14.22M | -13.19M | -13.17M | -13.58M | -13.76M |
| EPS Basic | -0.14 | -0.13 | -0.16 | -0.17 | -0.16 |
| Normalized Basic EPS | -0.09 | -0.08 | -0.10 | -0.10 | -0.10 |
| EPS Diluted | -0.14 | -0.13 | -0.16 | -0.17 | -0.17 |
| Normalized Diluted EPS | -0.09 | -0.08 | -0.10 | -0.10 | -0.10 |
| Average Basic Shares Outstanding | 86.94M | 86.94M | 81.23M | 81.23M | 80.87M |
| Average Diluted Shares Outstanding | 86.94M | 86.94M | 81.23M | 81.23M | 80.87M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |